A 2-year Prospective Study to Assess Health-related Quality of Life in Subjects with Highly-Active Relapsing Multiple Sclerosis Treated with Mavenclad
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Sep 2019
Price : $35 *
At a glance
- Drugs Cladribine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms CLARIFY MS
- Sponsors Merck KGaA
- 20 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 24 Jun 2019 Planned End Date changed from 25 Nov 2021 to 7 Jun 2021.
- 24 Jun 2019 Planned primary completion date changed from 25 Nov 2021 to 7 Jun 2021.